US Patent

US9757394 — Spironolactone aqueous formulations

Method of Use · Assigned to CMP Development LLC · Expires 2036-10-28 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition that includes spironolactone and various additives in an aqueous formulation.

USPTO Abstract

Disclosed herein is a pharmaceutical composition, comprising: (a) spironolactone; (b) a xanthan gum; (c) an anti-foaming agent; (d) a preservative; (f) a dispersing agent; (g) a sweetening agent; (h) a flavoring agent; (i) optionally a buffer to maintain the pH of the pharmaceutical composition within a range described herein; and (j) a sufficient amount of a water vehicle.

Drugs covered by this patent

Aldactone (spironolactone) · Generic (originally Searle/Pfizer)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2109`	—	Aldactone

Patent Metadata

Patent number: US9757394
Jurisdiction: US
Classification: Method of Use
Expires: 2036-10-28
Drug substance claim: No
Drug product claim: Yes
Assignee: CMP Development LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.